Clinical Trials - March 30, 2016
Oasmia enrolls first patient in Docecal study
Oasmia Pharmaceutical, a developer of drugs within human and veterinary oncology, announces that the first patient has been enrolled in the Phase I clinical study of the company’s cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015. Docecal is a nanoparticle and water-soluble formulation of docetaxel, one […]